Last reviewed · How we verify
NCT04614597
A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China
trial testing Sabin strain inactivated polio vaccine in Poliomyelitis in 774 participants. Completed in 21 December 2021.
21 December 2021
Quick facts
| Lead sponsor | Centers for Disease Control and Prevention, China |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 774 |
| Start date | 29 October 2020 |
| Primary completion | 21 December 2021 |
| Estimated completion | 21 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Sabin strain inactivated polio vaccine — full drug profile →
Conditions studied
- Poliomyelitis — all drugs for Poliomyelitis →
Sponsor
Centers for Disease Control and Prevention, China — full company profile →
Who can join
Adults 18 Months to 3, any sex, with Poliomyelitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In 2017, China CDC conducted a study titled "A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China". At present, all the infants in the monitoring cohort were over 18 months old and at least one year had elapsed since the last dose of sIPV inoculation.Since there is no any data about the protection duration of two-dose Sabin IPV schedules, China CDC propose to follow up the study cohort to evaluate the proportion of seroprotection of antibody and measure neutralizing antibody titers against poliovirus at over 18 months of age infants after a 2-dose or a 3-dose primary schedule of Sabin IPV in Chinese children.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04614597
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Poliomyelitis
Currently open trials in the same condition.
- NCT07457060 — Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine · Phase 4 · recruiting
- NCT06895486 — Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation · Phase 2 · recruiting
- NCT07354269 — Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations · Phase 4 · recruiting
- NCT06137664 — Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines · Phase 1, PHASE2 · recruiting
- NCT05644184 — Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh · Phase 2 · recruiting
Other Centers for Disease Control and Prevention, China trials
Trials by the same sponsor.
- NCT05298800 — Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 · Phase 4 · unknown
- NCT05087277 — Correlation Study of Isotype Switching and Neutralizing Capacity to the COVID-19 Variants Strain · unknown
- NCT05072496 — Study on Antibody Persistence and Immune Memory of Inactivated COVID-19 Vaccine · completed
- NCT03597919 — A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China. · Phase 4 · completed
- NCT03546634 — Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04614597 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centers for Disease Control and Prevention, China
- Last refreshed: 9 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04614597.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing